Humana’s Medicare Advantage plan announced that it will grant prior authorization for Lifeward Ltd.’s ReWalk 7 Personal Exoskeleton, a move that immediately opens the device to roughly 47 % of all Medicare Advantage beneficiaries nationwide. The decision follows a similar approval by UnitedHealthcare earlier in the month and represents the second major commercial insurer to cover the exoskeleton under a Medicare‑based benefit.
Lifeward’s Q3 2025 financial results provide context for the significance of the coverage expansion. The company reported revenue of $6.2 million, a 1.1 % year‑over‑year increase from $6.1 million in Q3 2024, and a net loss of $3.2 million. Management reaffirmed its full‑year 2025 revenue guidance of $24–$26 million and projected a non‑GAAP net loss of $12–$14 million, while securing a $3 million loan to extend its cash runway into the fourth quarter of 2026. The modest revenue growth and continued losses underscore the importance of new payer coverage for improving cash‑flow predictability.
The Humana authorization is a strategic win for Lifeward because it removes a key reimbursement barrier for a large segment of its target market. With Medicare Advantage now covering the ReWalk 7, the company can expect a measurable uptick in unit deliveries and reimbursement volume, which should help stabilize its cash‑flow profile and support ongoing investments in product development and market expansion. The coverage also signals to other insurers that the device meets the stringent criteria for Medicare reimbursement, potentially accelerating adoption across the industry.
The approval fits into a broader trend of payer adoption that began with the CMS Medicare reimbursement pathway for personal exoskeletons finalized in April 2024. Lifeward’s first commercial insurer approval came in April 2025, and the recent Humana decision confirms that the device is gaining traction beyond the initial Medicare pilot. This momentum is critical for Lifeward as it seeks to scale its business and achieve profitability in the second half of 2026.
Mark Grant, Lifeward’s CEO, emphasized that the Humana authorization “represents another significant milestone in payer adoption of the ReWalk 7. As coverage broadens and prior authorizations accelerate, we are seeing stronger predictability in reimbursement, healthier cash‑flow dynamics, and a clearer foundation for scalable, sustainable growth in the U.S. market.” The company’s guidance and management focus on cost discipline, coupled with the expanding payer base, suggest a cautious but optimistic outlook for the remainder of 2025 and beyond.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.